In FY 2008, the NIH received only a $300 million dollar increase and it may receive no increase in FY 2009 unless Congress alters the President's budget request.  These funding levels are significantly below the 3.5% increase needed simply to maintain NIH's existing purchasing power.  As a result of this funding level, coupled with small increases over the last few years, funding advocacy remains a top priority for the Society. 

During 2007, APOCC created and implemented an advocacy strategy to combat the difficult funding environment the research community finds itself in; the Committee plans to continue implementation of this plan throughout 2008. The plan is designed to address the changing advocacy challenges that face the research community in the post-doubling period. 

Biomedical Research Funding Position Statement

Bioequivalence of Sodium Levothyroxine Position Statement

Coalition for Health Funding: Senator Byrd on FY 2008 NIH Funding

Coalition for Health Funding: Senator Obey on FY 2008 NIH Funding

FY 2009 House Appropriations Committee Public Testimony on NIH Funding

Testimony of Carolyn Becker, MD, to the New York Medicaid Pharmacy and Therapeutics Committee on Levothyroxine Bioequivalence

Testimony of E. Chester Ridgway, MD, to the House Appropriations Committee on FY 2005 NIH Funding

Testimony of Marvin Gershengorn, MD, to the House Appropriations Committee on FY 2001 NIH Funding